title: Remoxipride and haloperidol in the acute phase of schizophrenia: a double-blind comparison.
abstract: The efficacy and safety of remoxipride in the treatment of schizophrenia were compared with those of haloperidol in a multicentre double-blind 6-week study which was randomized with a parallel group design and was preceded by a washout period. Eighty-nine consecutively admitted men and women meeting the Research Diagnostic Criteria for schizophrenia in an acute phase of the illness were treated with remoxipride 75-300 mg twice daily or haloperidol 5-20 mg twice daily. The efficacy assessments were the Brief Psychiatric Rating Scale, Krawiecka Rating Scale, and Clinical Global Impression. Both antipsychotic drugs produced clinical improvement with no significant differences between the efficacy of the two drugs. There were relatively few side effects. There were significantly fewer extrapyramidal symptoms and instances of blurred vision with remoxipride and less constipation with haloperidol. The results indicate that remoxipride is as effective an antipsychotic as haloperidol. Remoxipride has an advantage over haloperidol in respect to extrapyramidal side effects.
authors.affiliation: Oldham and District General Hospital, Lancashire, United Kingdom.
authors.forename: R
authors.initials: R
authors.lastname: Deo
authors.forename: S
authors.initials: S
authors.lastname: Soni
authors.forename: S C
authors.initials: SC
authors.lastname: Rastogi
authors.forename: S
authors.initials: S
authors.lastname: Levine
authors.forename: I
authors.initials: I
authors.lastname: Plant
authors.forename: J G
authors.initials: JG
authors.lastname: Edwards
authors.forename: M
authors.initials: M
authors.lastname: Mitchell
authors.forename: A
authors.initials: A
authors.lastname: Chanas
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000368:Aged; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001549:Benzamides / Q000009:adverse effects / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004409:Dyskinesia, Drug-Induced / Q000209:etiology; D005260:Female; D006220:Haloperidol / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009460:Neurologic Examination; D011569:Psychiatric Status Rating Scales; D011594:Psychometrics; D017330:Remoxipride; D012559:Schizophrenia / Q000188:drug therapy*; D012565:Schizophrenic Psychology
chemical_list: D014150:Antipsychotic Agents; D001549:Benzamides; D017330:Remoxipride; D006220:Haloperidol